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Abstract
Extracorporeal shock wave therapy (ESWT) is a non-
invasive treatment for chronic tendinopathies, however 
little is known about the in-vivo biological mechanisms 
of ESWT. Using microdialysis, we examined the real-time 
biological response of healthy and pathological tendons 
to ESWT. A single session of ESWT was administered to 
the mid-portion of the Achilles tendon in thirteen healthy 
individuals (aged 25.7 ± 7.0 years) and patellar or Achilles 
tendon of six patients with tendinopathies (aged 39.0 
± 14.9 years). Dialysate samples from the surrounding 
peri-tendon were collected before and immediately after 
ESWT. Interleukins (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, 
IL-12p70, IL-17A, vascular endothelial growth factor and 
interferon-γ were quantified using a cytometric bead array 
while gelatinase activity (MMP-2 and -9) was examined 
using zymography. There were no statistical differences 
between the biological tissue response to ESWT in healthy 
and pathological tendons. IL-1β, IL-2, IL-6 and IL-8 
were the cytokines predominantly detected in the tendon 
dialysate. IL-1β and IL-2 did not change significantly 
with ESWT. IL-6 and IL-8 concentrations were elevated 
immediately after ESWT and remained significantly 
elevated for four hours post-ESWT (p < 0.001). Pro-
forms of MMP-2 and -9 also increased after ESWT 
(p < 0.003), whereas there were no significant changes in 
active MMP forms. In addition, the biological response to 
ESWT treatment could be differentiated between possible 
responders and non-responders based on a minimum 5-fold 
increase in any inflammatory marker or MMP from pre- to 
post-ESWT. Our findings provide novel evidence of the 
biological mechanisms underpinning ESWT in humans in 
vivo. They suggest that the mechanical stimulus provided 
by ESWT might aid tendon remodelling in tendinopathy by 
promoting the inflammatory and catabolic processes that 
are associated with removing damaged matrix constituents. 
The non-response of some individuals may help to explain 
why ESWT does not improve symptoms in all patients and 
provides a potential focus for future research.
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Introduction
Tendons are highly organised, hierarchical structures that 
transmit muscular forces to the skeletal system for creating 
movement or for joint stability. For effective force transfer, 
tendons are required to be stiff, whilst some extensibility 
allows energy storage for efficient locomotion (Shepherd 
and Screen, 2013). Tendons must be able to withstand 
the forces generated through muscular loading. However, 
repetitive and/or excessive overloading of the tendon, 
such as that experienced with endurance running or poor 
biomechanics is considered to be the major aetiological 
factor in the development of tendinopathies (Huang et al., 
2004; Kader et al., 2002). Tendinopathies are a common 
and painful problem affecting both athletes (Kvist, 1991) 
and sedentary individuals (Rolf and Movin, 1997) causing 
a loss of function. Pathological changes, such as collagen 
fibre and fibril disorganisation, neovascularisation, and 
an increase in tenocyte proliferation and non-collagenous 
matrix quantity all provide evidence of a failed healing 
response to accumulated tendon damage (Astrom and 
Rausing, 1995; Jozsa and Kannus, 1997).
 There are a number of conservative treatment options 
which have been shown to improve the symptoms 
associated with tendinopathy, including physiotherapy, 
high-volume image-guided injections and eccentric loading 
(Coombes et al., 2010; de Vos et al., 2010; Sussmilch-
Leitch et al., 2012). Whilst some papers have questioned 
its efficacy (Costa et al., 2005; Zwerver et al., 2011), a 
recent systematic review demonstrated that extracorporeal 
shock wave therapy (ESWT) is also largely successful 
in providing an alternative conservative tendinopathy 
treatment (10/11 papers examining the efficacy of ESWT 
in Achilles tendinopathy, and 6/7 papers for the patellar 
tendon report a significant improvement in symptoms 
after treatment; Mani-Babu et al., 2014). ESWT is a 
non-invasive treatment in which the kinetic energy of 
acoustic shockwaves is concentrated on the area of pain 
and pathology, therefore applying mechanical forces to 
the tissue. Shockwaves are pressure waves, characterised 
by a rapid rise in positive pressure and high peak pressure 
amplitude, followed by a fall in pressure below ambient, 
i.e. negative pressure. The waves augment tissue density 
as a result of the positive and negative phases of the 
propagating wave passing through it, and in doing so 
deliver direct mechanical perturbations to the tissue. In the 
low-pressure phase of a passing shockwave, ESWT also 
causes cavitation (Ogden et al., 2001), characterised by the 
formation of gas bubbles. The implosion of the bubbles 
with the rise in pressure from the subsequent shock wave 
produces a secondary energy wave, which also provides a 
mechanical stimulus (Delius, 1994; Schmitz et al., 2013). 
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The mechanical perturbations generated by ESWT are 
likely to be of key importance to its treatment effect; due 
to the mechanosensitive nature of tendon cells, the impact 
of ESWT on interstitial and extracellular processes are 
theorised to initiate tissue regeneration (Ogden et al., 
2001).
 In vitro, using explant models and cell culture 
techniques, ESWT has been shown to enhance angiogenesis 
(Chen et al., 2004; Wang et al., 2003), and increase 
tenocyte proliferation, collagen synthesis (Vetrano et 
al., 2011), glycosaminoglycan (GAG) content, protein 
synthesis (Bosch et al., 2009; Bosch et al., 2007) and 
growth factors – such as transforming growth factor 
(TFG)-β1 – known to regulate tendon repair (Chen et 
al., 2004). It has also acted to decrease the presence of 
inflammatory cytokines (Han et al., 2009). Although 
insightful, such approaches have significant limitations, 
as the physiological environment of the tissue is not 
maintained, and thus it is difficult to relate findings to 
the in vivo response. In situ studies, which maintain the 
tissue’s physiological environment, have proven useful 
in assessing long-term structural changes resulting from 
ESWT treatment, such as potential reductions in tendon 
thickness (Wang et al., 2007). However, they provide no 
information regarding the biological environment of the 
tissue, or the immediate biological response of the tissue 
to the treatment. To our knowledge, little is known about 
the biological effect of ESWT on tendon tissue in vivo. 
Therefore, the mechanisms associated with the positive 
effect of ESWT on Achilles tendinopathy are currently 
unclear.
 Microdialysis can be used to examine the real-time 
biology of soft tissue intercellular spaces (Lonnroth et 
al., 1987) and has been used extensively in recent years 
to enrich our understanding of matrix turnover and 
metabolic processes occurring at a local tendon level at rest 
(Andersen et al., 2011), in response to mechanical loading 
(Koskinen et al., 2004; Langberg et al., 2002b), with injury 
(Alfredson et al., 2002), and during injury repair processes 
(Ackermann et al., 2013; Greve et al., 2012). The aim of 
this study was to examine the metabolic response of normal 
and tendinopathic tendons to ESWT treatment and provide 
the first in vivo evidence of the biological mechanisms 
underpinning ESWT treatment outcomes. Specifically, we 
investigated the acute response of inflammatory cytokines 
associated with mechanical loading, repair processes 
and tenocyte health (John et al., 2010; Thorpe et al., 
2015), and also matrix metalloproteases (MMPs), which 
are implicated in the homeostasis of tissue regeneration 
(Jones et al., 2013; Riley et al., 2002), for the purpose 
of improving our understanding of the mechanisms 
underlying observed effects.
Materials and Methods
Ethical approval and participant information
Institutional ethical approval was granted by the Queen 
Mary University of London ethics of research committee. 
The research was conducted in accordance with the 
Declaration of Helsinki guidelines. Thirteen participants 
with healthy tendons (herein referred to as ‘healthy 
participants’; 7 men, 6 women, aged 25.7 ± 7.0 years) 
were recruited from the university and general public 
by local and online advertisement. For inclusion into the 
study, healthy participants must not have had a previous 
tendinopathy or other tendon-related disorder (e.g. 
Haglund’s deformity or patello-femoral pain). Six patient 
participants (6 men, aged 39.0 ± 14.9 years) were recruited 
using leaflets displayed by local orthopaedic clinics and 
using an online advertisement published on a national 
running website. For inclusion into the study, patient 
participants were required to have an established (i.e. 
symptomatic for > 6 months) uni- or bi-lateral patellar or 
mid-portion Achilles tendinopathy, diagnosed by a suitably 
qualified healthcare professional. Patients were excluded 
from participation if they had received steroid, platelet-
rich plasma or high-volume image-guided injections in 
the previous 6 months, or had previous tendon surgery.
 All participants were required to be aged between 
18 and 65 years at the time of data collection and were 
screened for a history of systemic inflammatory conditions, 
anti-inflammatory medication prescriptions, and known 
allergy to or conditions contradicting the use of Lidocaine. 
All participants provided fully informed written consent 
and patient participants additionally completed a condition 
severity questionnaire (VISA-A or VISA-P for Achilles or 
patellar tendinopathy, respectively (Robinson et al., 2001; 
Visentini et al., 1998)) as a means of assessing pain and 
function. Data were collected from both tendons in some 
healthy participants, resulting in a total of 19 samples from 
the 13 healthy participants. For patient participants, data 
was collected from clinically pathological tendons only. 
Four patients had bilateral tendinopathy, leading to a total 
of 10 samples from the 6 patient participants. Patient and 
healthy participant demographics are presented in Table 1.
1A number of healthy participants consented to sampling from both tendons, and some patient 
participants had bilateral tendinopathy, so both number of participants and number of sample 
tendons are indicated for each group.
2VISA-A or VISA-P scores are provided for Achilles and patellar tendinopathy participants, 
respectively.
Table 1. Demographic information relating to healthy and patient groups.
Group Subject # Age Tendon Tendon # VISA score IL MMP
Healthy 1-8 24.4 ± 1.6 Achilles 10 - √ √
9-13 27.2 ± 9.9 Achilles 9 - x √
Patient 1-3 51.4 ± 8.7 Achilles 4 61.3 ± 8.3 √ √
4-6 26.7 ± 3.9 Patellar 6 41.0 ± 11.5 √ √
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Experimental protocol
Participants were instructed not to ingest anti-inflammatory 
drugs or partake in heavy exercise over the 48 h period 
prior to testing. All experiments started at approximately 
09.00 hours, and are shown schematically in Fig. 1. 
Participants lay prone (Achilles) or were seated (patellar) 
while the microdialysis probe was inserted. Due to a 
possible immediate biological response of the tissue to 
the trauma of the microdialysis probe insertion (Langberg 
et al., 1999), a 60 min wait period was introduced prior to 
commencing dialysate collection. From this point, dialysate 
was continually collected, and pooled over 30 min intervals 
to provide sufficient sample for analysis. Dialysate from 60-
90 min provided the baseline samples for MMP analysis; 
dialysate from 90-120 min provided the baseline sample 
for cytokine analysis. ESWT was administered to each 
tendon mid-portion (mean treatment size of 1-2 cm2) in a 
single session using a British kite-marked device (Swiss 
DolorClast® Classic, Electro Medical Systems, Nyon, 
Switzerland) and radial hand piece. Treatment was given 
perpendicular to the longitudinal tendon axis without 
anaesthesia and consisted of 2500 impulses administered 
at 8 Hz. The total energy delivered was 160 mJ/mm. After 
ESWT treatment, dialysate was collected every 60 min 
for the following 4 h. Achilles participants remained 
prone with the ankle joints in a relaxed neutral position 
(70-80°) throughout dialysate collection. For effective 
ESWT administration, the ankle was briefly moved to 
~85°. Patellar participants sat in Fowler’s position with 
a minimally flexed, supported knee (160-170°), for both 
dialysate collection and ESWT administration.
Microdialysis
The details of the procedure were based on the technique 
as described by Lonroth et al. (1987). Positioning the 
microdialysis catheters (Langberg et al., 2001) entailed 
a bilateral procedure under strict aseptic technique. For 
healthy participants, the skin either side of the free Achilles 
tendon was anaesthetised using subcutaneously injected 
Lidocaine (0.4-0.7 mL, 20 mg/mL), approximately 25 mm 
proximal to the calcaneal bone. For patient participants, 
the skin either side of the site with most pain and/or tendon 
thickening on palpation, depending on proximity to bony 
structures, was anaesthetised irrespective of the tendon 
type. Under ultrasound guidance (Voluson-I, GE Medical, 
Zipf, Austria), the active part of the microdialysis catheter 
was positioned in the peritendinous space (ventral to the 
Achilles tendon and superior to the patellar tendon). A 
high-precision fixed rate infusion pump (CMA 402, CMA 
Microdialysis AB, Kista, Sweden) perfused the catheter 
with sterile lactated Ringer’s solution at a rate of 2 μL/
min (Langberg et al., 2001). The dialysate fluid obtained 
from the probe outlet was collected in a centrifuge tube 
connected to the outlet tubing. Dialysate samples were 
immediately stored at ˗80 °C until further analysis.
Dialysate analysis
The profiles of interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, 
IL-10, IL-12p70, IL-17A, vascular endothelial growth 
factor (VEGF) and interferon (IFN)-γ were quantified by 
a cytometric bead array (healthy – human flex set, patient 
– human enhanced sensitivity flex set; BD Biosciences 
Pharmingen, San Diego, CA, USA). Samples were 
diluted 1:2 (vol/vol) before analysis. Briefly, samples and 
standards were incubated first with capture beads, and then 
detection reagents, to form sandwich complexes for each 
detectable cytokine. The complex formed for each cytokine 
could be differentiated based on its unique fluorescence 
characteristics, which were identified and quantified using 
flow cytometry (Accuri™ C6 and CFlow software, BD 
Biosciences Pharmingen).
 Gelatin zymography was used to quantitate the relative 
amounts of MMP-2 and MMP-9 activity at baseline, and 
also 1, 2 and 4 h after ESWT treatment. Zymography was 
performed using a 10 % sodium dodecyl sulphate (SDS) 
polyacrylamide gel containing 1 mg/mL gelatin, overlain 
with 5 % stacking gel. Samples were mixed 3:1 (vol/vol) 
with non-reducing loading buffer (200 mM Tris pH 6.8, 
4 % SDS, 0.1 % Bromophenol blue, 40 % glycerol) and 
20 µL loaded in each well. Electrophoresis was carried 
out at 150 V until the dye front had reached the bottom of 
the gel. Gels were rinsed twice in 2.5 % Triton X-100 and 
incubated in a development buffer (50 mM Tris pH 7.5, 
5 mM CaCl2) at 37 °C for 36 h. Gelatinase activity was 
revealed by negative staining with Coomassie Brilliant 
Blue. MMP-2 and MMP-9 standards (R&D Systems 
Europe Ltd, Abingdon, UK) were used as positive controls 
for gelatinase activity identification, and precision plus 
protein™ standard (Bio-Rad Laboratories, Hercules, CA, 
USA) was run on each gel to provide approximate protein 
sizes. 0.1 mM Ethylenediaminetetraacetic acid (EDTA) 
was added to the loading buffer, and 1 mM EDTA added 
to the development and rinse buffers of duplicate gels, to 
inhibit MMP activity on samples loaded onto the second 
gel, thus acting as a control. Gels were scanned with a Li-
Cor Odyssey scanner (Lincoln, NE, USA). Images were 
inverted and semi-quantitative densitometry performed 
using Image-J (NIH, Bethesda, MD, USA).
Statistical analysis
Data analysis was conducted with IBM SPSS version 20.0 
(IBM Corp, Armonk, NY, USA). All data are presented as 
Fig. 1. Schematic of protocol. Black arrows represent sampling time points.
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means ± standard error of the mean unless otherwise stated. 
Statistical analyses relating to the examination of cytokines 
were performed on data collected from 10 patient tendons 
and the first 10 healthy participant tendons that data were 
collected from (Table 1). For the purposes of calculating 
mean concentrations and performing statistical tests on the 
generated data set, analyte concentrations from dialysate 
samples found to be lower than the detection limit were set 
to the theoretical detection limit as described in the flex set 
data sheet (Ackermann et al., 2013). To allow a comparison 
of analyte concentrations between groups, the detection 
limits for the standard flex set were adopted for all samples. 
Detection thresholds for each cytokine were as follows: 
IL-1, 1,260 fg/mL; IL-2, 210 fg/mL; IL-4, 7,290 fg/mL; 
IL-6, 970 fg/mL; IL-8, 920 fg/mL; IL-10, 780 fg/mL; IL-
12, 9,600 fg/mL; IL-17, 11,350 fg/mL; IFN-γ, 9,300 fg/mL 
and VEGF, 2,200 fg/mL. Cytokine concentration data were 
log-transformed to control for heteroscedasticity. Baseline 
cytokine concentrations were compared between healthy 
and patient tendons using independent t-tests. Two-way 
analyses of variance (ANOVA) with repeated measures 
were used to examine each cytokine with respect to time 
(pre-ESWT and 1, 2, 3, 4 h post-ESWT) and group (healthy, 
patient). In the case of significance, a one-way ANOVA 
was performed for each dependent variable, followed 
by Bonferroni post hoc tests to identify the location of 
the significant differences between groups. Statistical 
significance was accepted at p < 0.05.
 Statistical analyses relating to the examination of 
MMP activity were performed for data collected from 
10 patient tendons and 19 healthy participant tendons 
(Table 1). Protein bands were identified as zymographic 
activity by comparing to the positive control standards 
and protein size ladder on each gel. To compare baseline 
MMP activity between groups, the relative density (i.e. 
intensity) of each protein band expressed at baseline was 
calculated as the fold-change in density from that of the 
9 µL MMP-2 and MMP-9 standards (1 ng/µL) run on 
each gel (a relative density of 1). Baseline MMP activity 
was compared between groups using a Mann-Whitney U 
test. The relative density of each protein band relating to 
a single data set was then calculated as the fold-change in 
density from that of the baseline sample. Friedman test 
for non-parametric data was used to compare each MMP 
before and 1, 2 and 4 h after ESWT for each group. In the 
case of significance, Wilcoxon’s signed rank tests were 
used to identify where differences were located. Statistical 
significance was accepted at p < 0.05.
Results
Inflammatory cytokines
IL-1β, IL-2, IL-6 and IL-8 were detected in both healthy 
and patient tendons. Low levels of IL-10 and IFN-γ were 
detected in some patient tendons (40 % and 30 % detection 
rate, respectively), but not in healthy tendons; all other 
cytokines investigated were below detection levels or not 
present in the dialysate. Due to low detection rates of IL-
10 and IFN-γ, statistical analysis was performed on IL-1β, 
IL-2, IL-6 and IL-8 only. Independent t-tests performed on 
baseline cytokine concentrations demonstrated a significant 
lower concentration of IL-2 in patients than in healthy 
tendons pre-ESWT (p = 0.005); there was no significant 
difference in baseline concentrations of IL-1, -6 or -8 
(p = 0.123-0.208, Fig. 2a). Results of the repeated measures 
ANOVAs established that there were no time-by-group 
interactions for any cytokine examined. There were main 
Fig. 2. a) Mean (+SD) concentration of interleukin (IL)-1β, 2, 6 and 8 exhibited by healthy (grey bars, n = 10) and 
patient (black bars, n = 10) tendons at baseline, and b) MMP expression exhibited by healthy (grey bars, n = 18) 
and patient (black bars, n = 10) tendons at baseline. MMP expression was calculated relative to the densities of 9 µL 
MMP-2 and -9 standards (1 ng/µL) run on each gel, determined using densitometry. * p < 0.05.
272 www.ecmjournal.org
CM Waugh et al.                                                                                    Response of tendinopathy to shockwave therapy
effects of time for IL-1β (F(1,18) = 2.754, MSE = 0.429, 
p = 0.034), IL-6 (F(1,18) = 29.745, MSE = 20.116, 
p < 0.001) and IL-8 (F(1,18) = 24.990, MSE = 14.653, 
p < 0.001), but not for IL-2 (F(1,18) = 1.005, MSE = 0.185, 
p = 0.411). The individual ANOVA results demonstrated 
elevated levels of IL-6 and IL-8 post-ESWT for both 
healthy (p = 0.001) and patient tendons (p = 0.001) and 
concentrations remained significantly elevated 4 h post-
ESWT (Fig. 3). The main effect of time for IL-1β was 
not demonstrated when groups were analysed separately.
Matrix metalloproteinase activity
MMP-2 activity was detected at ~135, 72 and 62 kDa. 
MMP-9 activity was detected at 92 and 82 kDa (Fig. 4). 
EDTA inhibited all MMP activity, confirming that bands 
seen on the zymogram were a result of MMP activity. 
Pro-MMP forms were more strongly detected than active 
forms. Densitometry data from baseline dialysate samples 
demonstrated significantly lower gelatinase activity of 
MMP-9 (82 kDa) in the patient group (U = 24, p = 0.001) 
pre-ESWT; there were no differences in MMP activity 
at any other molecular weight between groups (Fig. 2b). 
MMP-2 complex (135 kDa) and pro-MMP-9 (92 kDa) 
activity were significantly elevated post-ESWT relative 
to baseline in both healthy and patient groups (135 kDa, 
χ2(3) = 14.200, p = 0.003; 92 kDa, χ2(3) = 17.325, 
p = 0.001), whereas pro-MMP-2, and active MMP-2 and -9 
did not change significantly at any time point after ESWT 
(Fig. 5). The large within-group variability in MMP data, 
which may be responsible for the lack of detectable changes 
at certain time points, appears to be a result of a response 
or non-response to ESWT. Responders were defined as 
exhibiting a minimum 5-fold increase in any MMP at any 
time point post-ESWT when compared to baseline values 
(response rate of 22 % and 60 % in healthy and patient 
tendons, respectively; Fig. 6).
Fig. 3. Concentration of interleukin (IL)-1β, 2, 6 and 8 before and 1, 2, 3 and 4 h after ESWT in healthy (filled 
diamonds, n = 10) and tendinopathic (open diamonds, n = 10) tendons. IL-6 and IL-8 demonstrate significantly elevated 
concentrations post-ESWT when compared with pre-treatment concentrations and remained significantly elevated 
4 h post-ESWT. * Different from baseline value (p < 0.05); † different from baseline (p < 0.1); § different from post 
1 h (p < 0.05); ‡ different from post 1 h (p < 0.1); # different from post 2 h (p < 0.05). Black and grey symbols refer 
to patients and healthy groups, respectively.
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Discussion
The present study demonstrates an immediate and 
significant increase in some inflammatory and metabolic 
markers in response to ESWT in both healthy and 
pathological tendons. To our knowledge, these findings 
are the first to document the immediate in vivo, biological 
response of both healthy and pathological tendons to 
ESWT, and provide a novel insight into the mechanisms 
underpinning the effect of ESWT when used as a treatment 
for non-insertional tendinopathies, showing distinct 
molecular responders and non-responders based on a single 
session of ESWT.
Inflammatory cytokines
Inflammatory cytokines IL-1β, IL-2, IL-6 and IL-8 were 
detected in both healthy and patient tendons. No other 
cytokines were detected in healthy tendons, whilst low 
levels of IL-10 and IFN-γ were detected in some patient 
tendons. These resting cytokine profiles are largely in 
keeping with those reported by Ackermann et al. (2013) 
for healthy tendons, although their study reported a mean 
concentration of 2.5 pg/mL for IL-10 in healthy tendons 
which is significantly greater than the detection threshold 
for IL-10 in the current study (0.78 pg/mL). Cytokines 
can have a potent effect, even at picomolar concentrations 
(Dakin et al., 2014). Although this may represent a genuine 
difference between the participants recruited to each study, 
Ackermann et al. used the contralateral tendon of patients 
with uni-lateral Achilles tendinopathy as their healthy 
tendon comparison, so may have seen a contralateral 
effect, due to the study’s within-subject design (Andersson 
et al., 2011).
 Resting levels of IL-2 were significantly lower in 
patient tendons than healthy tendons in the current study, 
similar to the down-regulation of IL-2 seen in degenerative 
rat supraspinatus tendons (Millar et al., 2009). IL-2 is a 
pro-inflammatory mediator, produced and stored by T-cell 
lymphocytes. Although there is little other evidence of the 
direct involvement of IL-2 in tendinopathy, T-cells are 
important in the onset of several inflammatory diseases. 
Despite the on-going debate regarding inflammation in 
tendinopathy (Rees et al., 2014), we might speculate that 
lower levels of IL-2 in chronic tendinopathy patients reflects 
a reduced T-cell presence in comparison to healthy tendons 
– although there is evidence to suggest the opposite may 
be true (Schubert et al., 2005). There were no differences 
in the concentrations of IL-1, -6 or -8 between groups at 
baseline. This finding is not altogether surprising given the 
lack of consensus from published literature on the topic. 
For example, IL-1β may be increased (Gotoh et al., 1997; 
Hosaka et al., 2002) or show no difference (Ackermann et 
al., 2013; Pingel et al., 2012) in tendinopathy compared to 
Fig. 4. Example zymogram. The protein size ladder is 
situated in the leftmost column followed by the results 
of the MMP standards in columns 2-5 and microdialysis 
samples in columns 6-9.
Fig. 5. Fold change in matrix metalloprotease (MMP) expression before and after a single session of ESWT in healthy 
(n = 18) and patient (n = 10) tendons. Expression relative to a baseline expression of 1. * Different from baseline value 
(p < 0.05); § different from post 1 h (p < 0.05); ‡ different from post 1 h (p < 0.1); # different from post 2 h (p < 0.05).
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healthy tendons. Similarly, IL-6 may be greater (Legerlotz 
et al., 2012; Millar et al., 2009) or no different (Pingel et 
al., 2012) in tendinopathy.
 Concentrations of IL-6 and IL-8 increased significantly 
after ESWT and showed no sign of returning to baseline 
within the post-ESWT sampling period. There was no 
significant difference in the cytokine response between 
healthy and patient tendons. Our findings are in contrast 
to those of Han et al. (2009), who reported a decrease in 
IL-6 after ESWT was administered to tenocytes cultured 
from tendinopathic human Achilles tendons, but no 
change in IL-6 in cells cultured from healthy tendon. In 
the same study, IL-1β increased ~4-fold in tenocytes from 
healthy Achilles after ESWT, which is also in contrast to 
our finding that IL-1β did not change in either group at 
any time point examined. These disagreements between 
studies may be due to differences in the in vitro and in vivo 
experiments. Firstly, the cultured tenocytes were not in a 
physiologically or mechanically relevant environment, 
therefore unlikely to respond in the same way as they 
would in situ. Moreover, the authors do not describe 
which of the four shockwave conditions (250, 500, 1000 
or 2000 shocks) their IL-6 data represents, so it is difficult 
to compare this data to our results and the findings of other 
studies. Lastly, different devices were used to generate 
the shockwaves in each study, which have been shown to 
produce pressure waves with distinctly different physical 
characteristics (van der Worp et al., 2013). Specifically, 
the energy flux density of pressure waves delivered using 
a radial handpiece is highest at the applicator tip and 
reduces the further it travels due to a convex waveform 
(current study), whereas pressure waves delivered using 
a focused handpiece converge to concentrate energy at a 
specific depth (Schmitz et al., 2013). Currently, there is a 
lack of research detailing the significance of pressure wave 
shape and delivery method on tendon tissue biology (Maier 
and Schmitz, 2008; van der Worp et al., 2013), although 
the response of tenocyte monolayers to soft-focused 
shockwaves (a third type of shockwave which maintains 
the temporal characteristics of a focused shockwave, but 
applies the stimulus to a larger focal area) was recently 
examined (de Girolamo et al., 2014). Not only did this 
study deliver the same total energy as the current study, but 
the monolayer provided some cell-to-cell contact which is 
important for mechanotransduction. The authors reported 
an increase in IL-6 24 h after shockwave administration, 
which is in support of our findings.
 IL-6 is a multifunctional inflammatory cytokine, which 
demonstrates both pro- and anti-inflammatory actions and 
is released in response to mechanical loading. In vitro, 
human tenocytes demonstrate increased levels of IL-6 
in response to cyclic stretching (Legerlotz et al., 2013; 
Skutek et al., 2001). Further, exercise-induced increases 
in IL-6 were found in vivo in the Achilles peritendinous 
space after a period of running (Langberg et al., 2002b). 
Importantly, IL-6 has been shown to stimulate fibroblasts 
to increase the production of various extracellular matrix 
(ECM) components (Duncan and Berman, 1991) including 
Fig. 6. Change in MMP expression from baseline (pre-ESWT) in a) healthy (n = 18) and b) patient (n = 10) tendons, 
represented as responders (solid black lines) and non-responders (dashed grey lines). Responders were classified as 
demonstrating a minimum 5-fold increase in any MMP at any time point post-ESWT when compared to baseline 
values. Individual responders are presented with a unique marker, traceable across graphs. Approximately 4/18 (22 %) 
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collagen, with and without the presence of a mechanical 
stimulus (Andersen et al., 2011), suggesting that IL-6 
is a key regulator of connective tissue health. Given the 
mechanical nature of shockwaves, an increase in IL-6 after 
ESWT may facilitate tendon adaptation (Andersen et al., 
2011; Lin et al., 2005) or healing processes (Ackermann et 
al., 2013; Lin et al., 2006). Whilst there are many studies 
advocating the role of IL-6 in tendon adaptation, IL-6 may 
also promote negative effects. IL-6 has been shown to 
play a role in fibroblast proliferation (Mihara et al., 1995) 
and neoangiogenesis during tendon healing (Nakama et 
al., 2006), which have been implicated in tendinopathy. 
These conflicting arguments demonstrate the necessity for 
further research into tendinopathy-specific inflammatory 
and healing pathways before extensive conclusions can be 
drawn from our data.
 To our knowledge, this is the first study to report an 
IL-8 response to ESWT in any connective tissue. IL-8 is 
an important pro-inflammatory chemokine, which can 
be stored and released from many cell types, including 
neutrophils and activated fibroblasts (Hoffmann et al., 
2002). It has a potent chemoattractant activity, which 
attracts and activates neutrophils, triggering further 
IL-8 release (Masure et al., 1991). The rapid infiltration 
of neutrophils to a tissue is considered the primary 
inflammatory response and neutrophil degranulation 
releases enzymes which begin the process of degrading 
injured tissue. Although IL-8 can be rapidly induced by 
pathogens (Eckmann et al., 1993) and pro-inflammatory 
cytokines TNF-α and IL-1β (Kasahara et al., 1991), we 
suspect from our results that the mechanism is mechanical 
in nature. There is a surprising lack of literature to support 
the induction of IL-8 by mechanical loading in connective 
tissue, given that the biological mechanisms of IL-8 are 
well documented (Baggiolini and Clark-Lewis, 1992). 
However, mechanically induced up-regulation of IL-8 is 
not new; shear stresses and mechanical stretch increase 
IL-8 gene expression (Cheng et al., 2007) and secretion 
(Iwaki et al., 2009; Okada et al., 1998) in vascular 
endothelial cells, while vibration and oscillatory pressure 
changes increase IL-8 secretion in bronchial epithelium 
(Huang et al., 2012; Puig et al., 2005).
 An additional feature of shockwave therapy that has 
not yet been discussed in relation to these study results 
is the deformation to the tendon resulting from pressure 
with which the applicator tip is held against the tendon. 
As tenocytes perceive tissue deformation resulting from 
mechanical loading rather than the actual force applied, 
and given the particularly superficial nature of the tendons 
investigated here, the potential for this effect may be 
more pertinent in the present study. Unfortunately, this 
application pressure was not controlled for presently, 
and the stiffness of the tissues was not known, therefore 
any resulting tissue deformation could not be estimated. 
Nonetheless, the potential for this effect should be 
considered in future biological studies.
Matrix metalloproteinase activity
MMPs are involved in tendon tissue turnover and, in 
balance with their tissue inhibitors (TIMPs), are important 
in maintaining tendon homeostasis. MMP-2 activity was 
detected at ~135, 72 and 62 kDa and MMP-9 activity at 
92 and 82 kDa, confirmed with EDTA controls. Consistent 
with previous studies, pro-MMP forms were more strongly 
detected than active forms (Koskinen et al., 2004). This 
is likely due to the fact that: 1) only basal levels of active 
MMPs are required to perform the proteolytic activities 
required for constant ECM remodelling (Bode and Maskos, 
2003), unless the tissue is responding to injury or changes 
in loading (Snoek-van Beurden and Von den Hoff, 2005); 
and 2) MMPs are synthesised in a latent form, and once 
secreted, require extracellular activation by other MMPs.
 Lower resting MMP-9 (82 kDa) activity was found 
in tendinopathy patients in the current study whilst no 
difference was found for MMP-2. Whilst overproduction 
of MMPs may lead to tissue destruction in chronic 
inflammatory conditions (e.g. osteoarthritis; Tetlow et al., 
2001), underproduction may suggest an accumulation of 
pathological tissue. This hypothesis is in keeping with the 
histopathological findings of degenerative tendinopathy, 
which include collagen disorganisation and an increase 
in ECM constituents (Järvinen et al., 1997; Khan et al., 
1999). In support of our findings, Riley et al. (2002) 
reported lower MMP-9 activity in pathological human 
tendons, whilst Jones et al. (2006) found no difference 
in MMP-2 mRNA expression in normal, degenerate and 
ruptured human tendons. However, these findings are 
somewhat in contrast to other studies. Pingel et al. (2012) 
reported significantly elevated MMP-2 and MMP-9 mRNA 
expression in tendinopathic biopsies compared to healthy 
biopsies from human Achilles tendons. Parkinson et al. 
(2010) found an increased MMP-9 mRNA expression in 
chronic patellar tendinopathy. Jones et al. (2006) described 
higher levels of MMP-9 mRNA in ruptured compared 
with normal tendons, but no difference in tendinopathy. 
However, MMP activity is controlled on many levels and 
an increase in mRNA expression does not guarantee an 
increase in protein synthesis (Snoek-van Beurden and Von 
den Hoff, 2005), therefore we are limited in our ability to 
compare studies.
 An increase in the MMP-2 component with the largest 
molecular mass (~135 kDa) was found relative to baseline 
after ESWT in both healthy and patient groups. MMP-2 
has been shown to form a reduction-sensitive homodimer, 
whose high molecular mass is approximately twice that 
of the active monomer (Koo et al., 2012). Dimerisation 
has been suggested as a mechanism for regulating MMP-
2 activity and is thought to occur intracellularly, thus 
the homodimer is secreted into the ECM as an inactive 
MMP-2 form (Koo et al., 2012). Interestingly, neither 
pro- nor active MMP-2 increased significantly with ESWT, 
although increases in MMP-2 may not occur as rapidly 
as other MMPs; up-regulation of both pro- and active 
MMP-2 was only seen after two weeks of running in the rat 
supraspinatus (Attia et al., 2013) or three days of running 
intervention in the human Achilles tendon (Koskinen et al., 
2004). Alternatively, microdialysis may not be an optimal 
technique for detecting MMP-2 activity due to the cell-
bound mechanisms by which it is recruited and activated 
(Nagase, 1998).
 In contrast to the MMP-2 monomers, a marked increase 
in pro-MMP-9 expression was found immediately after 
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ESWT. Similar findings have been reported after a period 
of running exercise (Koskinen et al., 2004). In the present 
study, such large increases in pro-MMP-9 over the short 
time-frame from which dialysate was acquired suggests 
that intracellularly-stored MMP-9 is secreted into the 
extracellular space. However, levels of active MMP-9 did 
not change after ESWT, suggesting that latent forms are 
not automatically immediately activated. It is generally 
accepted that MMP-9 is produced and stored in its pro-form 
in the tertiary granules of neutrophils (Masure et al., 1991) 
and is rapidly released after IL-8-mediated neutrophil 
activation (Hasty et al., 1990). The increase in pro-MMP 9 
in the current study may be a result of the increase in IL-8 
seen immediately after ESWT administration, although 
TGF-β1 – an important mediator in mechanotransduction 
(Heinemeier et al., 2003) – has also been implicated in 
the mechanical regulation of MMPs (Jones et al., 2013). 
In keeping with the hypothesis that basal reparative 
activity is reduced in degenerative tendinopathy, an 
increase in MMP activity from baseline might indicate a 
positive mechanism, increasing the likelihood of tissue 
regeneration by increasing the pro-MMP forms availability 
for activation. However, TIMP activity was not examined 
currently, therefore we are limited in our ability to draw 
conclusions regarding these changes.
Responders versus non-responders
The lack of significance associated with the change in 
MMP activity in the current study might appear surprising 
given the clear increased activity observed after ESWT 
in some individuals. However, it is evident there are 
large inter-individual differences in the MMP response 
due to possible responders and non-responders (Fig. 6). 
In the case of our results, responders were identified as 
individuals demonstrating a minimum 5-fold increase in 
any MMP at any time point post-ESWT when compared 
to baseline values. Although we recognise the limitations 
and assumptions associated with categorising individual 
tendon responses from our limited data set in this manner, 
this arbitrary threshold was chosen based on a natural 
separation of data around this point, leading to an intuitive 
method of characterising a complex dataset. The responder 
phenomenon becomes particularly interesting when 
considering the clinical effectiveness of ESWT. Based on 
good or excellent improvement in condition symptoms 
following a ESWT treatment course, success rates of 52-
85 % for non-insertional Achilles (Furia, 2008; Rompe et 
al., 2007; Saxena et al., 2011; Vulpiani et al., 2009) and 
50-74 % for patellar tendinopathies (Peers et al., 2003; 
Vulpiani et al., 2007; Wang et al., 2007) are reported, 
which are similar to the percentage of patient tendons 
that responded to ESWT in the present study (60 %). It is 
possible that individuals whose tendinopathies improved 
with ESWT are individuals who would demonstrate a 
biological response to treatment. However, it should be 
emphasised that the response observed presently is to a 
single session of ESWT and may not necessarily reflect 
the individual’s response to a typical course of treatment. 
Unfortunately, we do not have the data necessary to 
investigate the relationship between molecular response 
and treatment effectiveness further as this was a somewhat 
surprising finding. Nonetheless, as this information could 
help optimise treatment results by informing dosage 
decisions, the relationship between treatment response and 
treatment outcome is of potential importance and should 
be made a priority for future research.
Limitations
Microdialysis allows continuous in vivo measurements 
of soluble molecules in the interstitial tissue space and 
therefore the time course of a tissue response to stimuli 
to be determined. However, there are limitations to its use 
as a sampling tool. Although minimally invasive, there 
is likely to be some local tissue trauma in response to 
positioning the microdialysis probe. Transient increases 
in inflammatory mediators TGF-1β (Heinemeier et al., 
2003), PGE2 and TXB2 (Langberg et al., 1999) have 
been identified immediately after catheter insertion, with 
mediator concentrations returning to baseline levels after 
~120-150 min. The effect of local tissue trauma was not 
examined for the interleukins or MMPs investigated 
in the present study, although we have carried out an 
additional study in which we confirmed that MMP activity 
is unchanged in the 90 min after probe insertion (Fullerton 
et al., 2014). In addition, samples used for investigating 
the interleukin baseline were not collected until 90-
120 min post probe insertion, which should minimise 
the inflammatory response to catheter insertion based on 
previously published work and study protocols.
 In addition to this limitation, whilst microdialysis aims 
to characterise the local intercellular water space based 
on the movement of unbound water-soluble substances 
across a semipermeable membrane, this space is largely 
continuous and thus we are unable to categorically state 
that the origin of the molecules present in the dialysate 
was from the tendon itself. Whilst we cannot differentiate 
between molecules that have diffused from the tendon and 
those from other local tissues, it has been shown previously 
that the tendon periphery is more metabolically active than 
the tendon core (Langberg et al., 2002a), thus positioning 
the microdialysis probe in the peritendinous space is likely 
to be more representative of tendon biology than any other 
location.
 Lastly, we did not screen individuals for asymptomatic 
tendinopathies using imaging modalities. Therefore, 
it is possible that individuals with non-symptomatic 
tendinopathies are included in our healthy tendon group. 
However, the prevalence of asymptomatic tendinopathy 
is relatively low in active young adults (3.8 %, Joseph et 
al., 2012) and the ability of imaging techniques to predict 
future symptomatic tendinopathy has also been questioned 
(Comin et al., 2013).
Conclusion
To our knowledge, these findings provide a novel 
insight into the biological mechanisms underpinning the 
observed clinical effects of ESWT in humans in vivo. Our 
findings suggest that the mechanical stimulus provided 
by ESWT might aid the initiation of tendon regeneration 
in tendinopathy by promoting pro-inflammatory and 
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catabolic processes that are associated with removing 
damaged matrix constituents. Our findings are supported 
by the association between IL-6 and collagen synthesis, 
and the IL-8 cascade which encourages neutrophils to 
release ECM-degrading enzymes. The response profile 
and time course of other biological indicators of matrix 
turnover and tendon regeneration are required to build 
upon the present findings, as are the effects of different 
ESWT treatment dosage protocols and devices. Our results 
also suggest the possibility of biological responders and 
non-responders to the ESWT protocol used presently, but 
requires further investigation to substantiate this claim. 
Knowledge of these mechanisms has the potential to help 
improve clinical paradigms concerning treatment decisions 
and protocols and therefore optimise efficacy for patients.
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Discussion with Reviewers
Reviewer II: The manuscript confirms the results of 
previous in vitro studies and brings new knowledge on 
the in vivo effect of ESWT in healthy and pathologic 
tendons. The expression of different cytokines induced by 
shock waves, in this as in other studies, seems to confirm 
that an adequate stimulus modulates the “physiological 
inflammatory sequence” which characterises the tendon 
healing process. Nevertheless, as described, the role of 
microdialysis seems to be restrictive to the earliest phases 
with respect to the molecular kinetics of the whole process. 
Finally, the manuscript highlights the question of the 
biological responders and non-responders to ESWT. This 
would give new impulse to the debate on the causes of the 
individual answers (success or failure) to physical stimuli 
in the treatment of tendinopathies.
Authors: We thank the reviewer for these comments and 
appreciate that they recognise the potential importance of 
our findings, in respect to both verifying the presence of 
cytokines in initiating tendon healing, and in evidencing 
that individuals may respond individually to treatment 
modalities. Whilst we agree that the role of microdialysis 
in determining some of the biological events that may 
underpin ESWT is limited, we hope that our study 
stimulates further research in the area and has identified 
avenues that should take priority for future research.
Reviewer III: Given the low number of participants, is 
it relevant to divide into non-responders and responders?
Authors: Although the patient group is not ideal with 
respect to size and homogeneity, we think that our findings 
are interesting enough to report. Moreover, the potential 
importance of these surprising findings may provide a 
rationale for future research.
Reviewer III: Is shock wave therapy effective in 
tendinopathy conditions other than those that have 
calcifications? Does it make sense to study biological 
changes in tendinopathy when we do not know whether 
the treatment is effective?
Authors: Shockwave therapy has been proven to be an 
effective treatment for non-calcific tendinopathy The 
results from our recent systematic review regarding this 
matter suggests that there is enough evidence from high-
quality studies evaluating the effectiveness of ESWT 
for lower limb tendinopathies (Achilles, patellar and 
greater trochanter) to conclude that ESWT is an effective 
intervention for tendinopathies (Mani-Babu et al., 2014). 
We conclude, based on the findings from this review, 
that the biological underpinning of ESWT continue to be 
investigated.
Reviewer III: Does peritendinous microdialysis reflect 
what goes on inside the tendon or does it rather reflect 
what happens along the tendon in for example fat tissue?
Authors: Microdialysis enables an analysis of local tissue 
biology in vivo whilst providing a new avenue to explore 
biological events in real time. It has been shown previously 
that the tendon periphery is more metabolically active 
than the tendon core (Langberg et al., 2002a; Rempel and 
Abrahamsson, 2001), and so peritendinous microdialysis 
is likely to be more representative of tendon biology 
from this perspective. However, we cannot differentiate 
between molecules that have diffused from the tendon 
and those from other local tissues such as fat, which is a 
methodological limitation.
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